A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC)

被引：3
|
作者：
Jhaveri, K. [1 ]
Chandarlapaty, S. [1 ]
Lake, D. [1 ]
Gilewski, T. [1 ]
Drullinsky, P. [1 ]
Sugarman, S. [1 ]
Wasserheit-Leiblich, C. [1 ]
Moynahan, M. E. [1 ]
D'Andrea, G. [1 ]
Haque, S. [1 ]
Patil, S. [1 ]
Bauman, L. [1 ]
Vukovic, V. [1 ]
El-Hariry, I. [1 ]
Hudis, C. [1 ]
Modi, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-17-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-17-08
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase I-II Trial of Dasatinib (D) in Combination with Weekly (w) Paclitaxel (P) for Patients (Pts) with Metastatic Breast Carcinoma (MBC)
    Morris, P. G.
    Abbruzzi, A.
    D'Andrea, G.
    Gilewski, T.
    Lake, D.
    Bromberg, J.
    Dang, C.
    Dickler, M.
    Modi, S.
    Seidman, A. D.
    Sklarin, N.
    Chang, J.
    Patil, S.
    Norton, L.
    Hudis, C. A.
    Fornier, M. N.
    CANCER RESEARCH, 2010, 70
  • [42] Vinorelbine-doxorubicin combination chemotherapy is an active and safe regimen for patients (PTS) with metastatic breast cancer (MBC): Updated results of a large Syrian phase II trial
    Youssef, Amer Al Chikh
    El Shatty, Iyad
    El Shatty, Rakan
    Haddad, Nadine
    ANNALS OF ONCOLOGY, 2006, 17 : 83 - 84
  • [43] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Peacock, N. W.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Greco, F. A.
    Farley, C.
    Webb, C.
    Spigel, D. R.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with hormone receptor-negative (HR-) metastatic breast cancer (MBC): Translational Breast Cancer Research Consortium trial 007
    Vaughn, L. G.
    Li, L.
    Nabell, L.
    Rugo, H. S.
    Carey, L. A.
    Kimmick, G. G.
    Steeg, P. S.
    Miller, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Phase I clinical trial of bavituximab (Bavi) and paclitaxel (P) patients (pts) with HER2-negative metastatic breast cancer (MBC)
    Chalasani, Pavani
    Marron, Marilyn
    Clarke, Kathryn
    Schmidt, Kathy
    Powell, Alisa
    Iannone, Maria
    Stopeck, Alison
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Phase II trial of biweekly gemcitabine, paclitaxel, and bevacizumab as frontline therapy for metastatic breast cancer (MBC)
    Nahleh, Z. A.
    Gupta, R.
    Abrams, J.
    Gartner, E. M.
    Reichle, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Phase I/II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC)
    Schwartzberg, Lee S.
    Blakely, Laura J.
    Schnell, Frederick
    Christianson, David
    Andrews, Michael
    Johns, Amanda
    Walker, Mark
    CANCER RESEARCH, 2011, 71
  • [48] Phase II trial of DPPE and doxorubicin chemotherapy in patients with metastatic breast cancer (MBC): A National Cancer Institute of Canada (NCIC) study
    Khoo, K
    Brandes, L
    Reyno, L
    Dent, S
    Vandenberg, T
    Lebwohl, D
    Fisher, B
    Eisenhauer, E
    ANNALS OF ONCOLOGY, 1998, 9 : 171 - 171
  • [49] Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC).
    Khoo, KS
    Zaidi, M
    Srimuninnimit, V
    Jiang, ZF
    Prem Kumar, P
    Bustam, A
    Villalon, AH
    Lehnert, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 54S - 54S
  • [50] Ixabepilone in patients (PTS) with metastatic breast cancer (MBC) that is resistant to an anthracycline, a taxane and capecitabine
    Pivot, Xavier
    Thomas, Eva
    Lerzo, Guillermo
    Bosserman, Linda
    Vahdat, Linda
    Cai, Can
    Mullaney, Brian
    Viens, Patrice
    Perez, Edith
    Hortobagyi, Gabriel N.
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 71
12345